Analyst Price Targets — NVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:16 am | — | HSBC | $112.00 | $131.01 | TheFly | Novartis price target raised to $112 from $106 at HSBC |
| December 3, 2025 11:33 am | — | Morgan Stanley | $143.00 | $132.28 | TheFly | Novartis price target raised to $143 from $136 at Morgan Stanley |
| October 29, 2025 3:42 pm | Wan Nurhayati | CFRA | $126.00 | $123.33 | StreetInsider | Novartis (NVS) PT Raised to $126 at CFRA |
| October 30, 2024 8:48 am | Etzer Darout | BMO Capital | $120.00 | $109.91 | StreetInsider | Novartis (NVS) PT Raised to $120 at BMO Capital |
| September 5, 2024 4:27 am | James Quigley | Goldman Sachs | $121.00 | $119.38 | TheFly | Novartis downgraded to Neutral from Buy at Goldman Sachs |
| July 19, 2024 9:06 am | Etzer Darout | BMO Capital | $118.00 | $106.13 | StreetInsider | Novartis (NVS) PT Raised to $118 at BMO Capital |
| April 23, 2024 1:11 pm | Wan Nurhayati | CFRA | $108.00 | $97.27 | StreetInsider | Novartis (NVS) PT Raised to $108 at CFRA |
Latest News for NVS
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells.
Banco Santander S.A. lowered its stake in shares of Novartis AG (NYSE: NVS) by 51.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,286 shares of the company's stock after selling 32,075 shares during the period. Banco Santander S.A.'s
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030 Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 --…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVS.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.